Werewolf Therapeutics Inc HOWL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if HOWL is a good fit for your portfolio.
News
-
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
-
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting
-
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting
-
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference
-
Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024
Trading Information
- Previous Close Price
- $6.39
- Day Range
- $6.00–6.30
- 52-Week Range
- $1.57–8.19
- Bid/Ask
- $6.01 / $6.08
- Market Cap
- $262.03 Mil
- Volume/Avg
- 36,274 / 205,571
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 11.51
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 47
- Website
- https://www.werewolftx.com
Comparables
Valuation
|
Metric
|
HOWL
|
EQRX
|
ACLX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.26 | 0.97 | 5.69 |
Price/Sales | 11.51 | — | 23.01 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
HOWL
|
EQRX
|
ACLX
|
|---|---|---|---|
Quick Ratio | 7.00 | 18.43 | 5.94 |
Current Ratio | 7.14 | 18.78 | 6.06 |
Interest Coverage | −13.27 | — | −23.39 |
Quick Ratio
HOWL
EQRX
ACLX
Profitability
|
Metric
|
HOWL
|
EQRX
|
ACLX
|
|---|---|---|---|
Return on Assets (Normalized) | −16.46% | −15.72% | −6.26% |
Return on Equity (Normalized) | −25.06% | −16.71% | −12.08% |
Return on Invested Capital (Normalized) | −20.75% | −21.31% | −13.11% |
Return on Assets
HOWL
EQRX
ACLX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Vbkfmwfc | Hfjyn | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Dtxynzsyc | Zjcfrq | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jfysgvzw | Yykphn | $99.5 Bil | |
MRNA
| Moderna Inc | Ybrkdgrdf | Xzqyl | $38.8 Bil | |
ARGX
| argenx SE ADR | Xzlbbrgh | Vthrb | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Pllftvjb | Gzwvb | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Xqbckqmvx | Ppshwx | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Rhdylfs | Pnbcwdj | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Wcxzwtmbr | Tygxp | $12.5 Bil | |
INCY
| Incyte Corp | Zkgzyfrl | Rdfsmn | $11.6 Bil |